After a very quick read all looks good IMHO..
The SARAH study has been awarded an Oral Abstract at the meeting and will be presented in the General Session III on Saturday, 22nd April 2017 between 10-10:15 am local time. The Oral Abstract is entitled “SARAH: a randomised controlled trial comparing efficacy and safety of selective internal radiation therapy (with yttrium-90 microspheres) and sorafenib in patients with locally advanced hepatocellular carcinoma.”
Details of the EASL/ILC 2017 Press Programme can be found at the following link: https://ilc-congress.eu/pressprogramme/
Ann: SARAH Abstract Embargoed Until EASL/ILC Meeting, page-2
-
- There are more pages in this discussion • 81 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add SRX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
18.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $77.74M | |||
| Open | High | Low | Value | Volume |
| 18.0¢ | 18.0¢ | 18.0¢ | $10.1K | 56.10K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 36209025 | 18.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 18.5¢ | 4384259 | 22 |
View Market Depth
| Last trade - 15.18pm 13/09/2024 (20 minute delay) ? |
| SRX (ASX) Chart |